Document is current

Article History

Received: 20 April 2026

Accepted: 5 June 2026

First Online: 16 June 2026

Declarations

:

: Not applicable.

: MG received travel grants, compensation for advisory boards, research founding or speaker’s fees from AbbVie, Amgen, AstraZeneca, Eli Lilly, Hexal, Janssen, Novartis, Pfizer, SOBI, Takeda, UCB. MS received compensation for advisory boards from AbbVie, Alfasigma/Galapagos, AstraZeneca, BMS, Boehringer/Ingelheim, EUSA-Pharma/Recordati, Johnson&Johnson, Novartis, onkowissen.de, Sanofi, SOBI, UCB; speaker’s fees from AbbVie, Alfasigma/Galapagos, BMS, Boehringer/Ingelheim, EUSA-Pharma/Recordati, Johnson&Johnson, Lilly, Merck, Novartis, onkowissen.de, Pfizer; travel grants from AbbVie, Alfasigma/Galapagos, Boehringer/Ingelheim, Johnson&Johnson, UCB; research funding Chugai, Novartis, AbbVie. HL travel grants, compensation for advisory boards or speaker’s fees from Eli Lilly, Janssen, Novartis, Abbvie, Pfizer, Alfasigma, Boehringer/Ingelheim, Celltrion, and UCB. YZ has no conflicts of interest to declare. PPS received research funding from Chugai, Novartis, and AbbVie as well as travel grants or speaker fees from AbbVie, Novartis, Johnson&Johnson/Janssen, and UCB. MF has received travel grants or speaker`s fees from AbbVie, Janssen, Novartis, Eli Lilly. PEH has no conflicts of interest to declare. AKB has received speaker honoraria from Novartis/AAA and PentixaPharm, is a board member/officer/trusted for PentixaPharm. RAW has received speaker honoraria from and reports advisory board work for Novartis/AAA. SES received compensation for advisory boards from Novartis.